Goldman Sachs’s GT Biopharma GTBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-762
| Closed | -$5.83K | – | 4823 |
|
|
2023
Q4 | $5.83K | Buy |
762
+415
| +120% | +$3.18K | ﹤0.01% | 4682 |
|
|
2023
Q3 | $2.51K | Sell |
347
-3
| -0.9% | -$22 | ﹤0.01% | 4676 |
|
|
2023
Q2 | $3.28K | Hold |
350
| – | – | ﹤0.01% | 4865 |
|
|
2023
Q1 | $5.78K | Sell |
350
-2
| -0.6% | -$33 | ﹤0.01% | 4998 |
|
|
2022
Q4 | $9.34K | Sell |
352
-482
| -58% | -$12.8K | ﹤0.01% | 4948 |
|
|
2022
Q3 | $44K | Buy |
834
+479
| +135% | +$25.3K | ﹤0.01% | 5051 |
|
|
2022
Q2 | $32K | Sell |
355
-1
| -0.3% | -$90 | ﹤0.01% | 5361 |
|
|
2022
Q1 | $31K | Sell |
356
-2,018
| -85% | -$176K | ﹤0.01% | 5544 |
|
|
2021
Q4 | $217K | Buy |
2,374
+626
| +36% | +$57.2K | ﹤0.01% | 4955 |
|
|
2021
Q3 | $353K | Buy |
+1,748
| New | +$353K | ﹤0.01% | 4574 |
|